BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 10097126)

  • 21. Possible implication of NFKB1A and NKG2D genes in susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis in Peruvian patients infected with HTLV-1.
    Talledo M; López G; Huyghe JR; Verdonck K; González E; Clark D; Vanham G; Gotuzzo E; Van Camp G; Van Laer L
    J Med Virol; 2012 Feb; 84(2):319-26. PubMed ID: 22170554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.
    Kozako T; Yoshimitsu M; Akimoto M; White Y; Matsushita K; Soeda S; Shimeno H; Kubota R; Izumo S; Arima N
    Hum Immunol; 2011 Nov; 72(11):1001-6. PubMed ID: 21851845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High IFN-γ/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis development.
    Espíndola OM; Oliveira LC; Ferreira PM; Leite AC; Lima MA; Andrada-Serpa MJ
    Intervirology; 2015; 58(2):106-14. PubMed ID: 25833232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1.
    Manuel SL; Sehgal M; Khan ZK; Goedert JJ; Betts MR; Jain P
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1273-85. PubMed ID: 23750452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network.
    Goncalves DU; Proietti FA; Barbosa-Stancioli EF; Martins ML; Ribas JG; Martins-Filho OA; Teixeira-Carvalho A; Peruhype-Magalhães V; Carneiro-Proietti AB
    Inflamm Allergy Drug Targets; 2008 Jun; 7(2):98-107. PubMed ID: 18691139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus].
    Carod-Artal FJ
    Rev Neurol; 2009 Feb 1-15; 48(3):147-55. PubMed ID: 19206063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of TSLC1 in patients with HAM/TSP.
    Takenouchi N; Tanaka M; Sato T; Yao J; Fujisawa JI; Izumo S; Kubota R; Matsuura E
    J Neurovirol; 2020 Jun; 26(3):404-414. PubMed ID: 32285300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmatic proinflammatory chemokines levels are tricky markers to monitoring HTLV-1 carriers.
    Chaves DG; Sales CC; de Cássia Gonçalves P; da Silva-Malta MC; Romanelli LC; Ribas JG; de Freitas Carneiro-Proietti AB; Martins ML
    J Med Virol; 2016 Aug; 88(8):1438-47. PubMed ID: 26800845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Degenerate specificity of HTLV-1-specific CD8+ T cells during viral replication in patients with HTLV-1-associated myelopathy (HAM/TSP).
    Kubota R; Furukawa Y; Izumo S; Usuku K; Osame M
    Blood; 2003 Apr; 101(8):3074-81. PubMed ID: 12480698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness.
    Adaui V; Verdonck K; Best I; González E; Tipismana M; Arévalo J; Vanham G; Campos M; Zimic M; Gotuzzo E
    J Neurovirol; 2006 Dec; 12(6):456-65. PubMed ID: 17162661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease.
    Sabouri AH; Usuku K; Hayashi D; Izumo S; Ohara Y; Osame M; Saito M
    Blood; 2008 Sep; 112(6):2411-20. PubMed ID: 18502825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Target epitopes of HTLV-1 recognized by class I MHC-restricted cytotoxic T lymphocytes in patients with myelopathy and spastic paraparesis and infected patients with autoimmune disorders.
    Kozako T; Akimoto M; Toji S; White Y; Suzuki S; Arima T; Suruga Y; Matsushita K; Shimeno H; Soeda S; Kubota R; Izumo S; Uozumi K; Arima N
    J Med Virol; 2011 Mar; 83(3):501-9. PubMed ID: 21264872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of association between single-nucleotide polymorphisms of pro- and anti-inflammatory cytokines and HTLV-1-associated myelopathy / tropical spastic paraparesis development in patients from Rio de Janeiro, Brazil.
    Schor D; Porto LC; Roma EH; Quintana MSB; Fabricio-Silva GM; Bonecini-Almeida MG; Araújo AQ; Andrada-Serpa MJ
    BMC Infect Dis; 2018 Nov; 18(1):593. PubMed ID: 30466392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased HTLV type 1 tax specific CD8+ cells in HTLV type 1-asociated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load.
    Kubota R; Nagai M; Kawanishi T; Osame M; Jacobson S
    AIDS Res Hum Retroviruses; 2000 Nov; 16(16):1705-9. PubMed ID: 11080814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy/tropical spastic paraparesis from a Brazilian cohort: ROC curve analysis to establish the threshold for risk disease.
    Furtado Mdos S; Andrade RG; Romanelli LC; Ribeiro MA; Ribas JG; Torres EB; Barbosa-Stancioli EF; Proietti AB; Martins ML
    J Med Virol; 2012 Apr; 84(4):664-71. PubMed ID: 22337307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological aspects of tropical spastic paraparesis/HTLV-I associated myelopathy and HTLV-I infection.
    Gessain A
    J Neurovirol; 1996 Oct; 2(5):299-306. PubMed ID: 8912206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population.
    Best I; López G; Verdonck K; González E; Tipismana M; Gotuzzo E; Vanham G; Clark D
    Immunology; 2009 Sep; 128(1 Suppl):e777-86. PubMed ID: 19740339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru.
    Best I; Adaui V; Verdonck K; González E; Tipismana M; Clark D; Gotuzzo E; Vanham G
    Clin Exp Immunol; 2006 Nov; 146(2):226-33. PubMed ID: 17034574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of host genetic and viral factors as surrogate markers for HTLV-1-associated myelopathy/tropical spastic paraparesis in Peruvian HTLV-1-infected patients.
    Talledo M; López G; Huyghe JR; Verdonck K; Adaui V; González E; Best I; Clark D; Vanham G; Gotuzzo E; Van Camp G; Van Laer L
    J Med Virol; 2010 Mar; 82(3):460-6. PubMed ID: 20087941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP.
    Grassi MF; Olavarria VN; Kruschewsky Rde A; Mascarenhas RE; Dourado I; Correia LC; de Castro-Costa CM; Galvão-Castro B
    J Med Virol; 2011 Jul; 83(7):1269-74. PubMed ID: 21567429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.